BioNTech’s ASCO Bet on Pumitamig Carries Outsize Weight as Cash Pile Buys Time but Not Validation

BioNTech shares rose 2.75% but remain 14% down monthly; focus turns to May 29 ASCO phase 2 pumitamig data vs Keytruda in lung cancer. Strong cash position offsets declining revenue.

BioNTech’s stock staged a modest recovery on Friday, closing at €80.45 on Xetra — a 2.75% gain from the previous session — but the advance does little to mask the deeper anxiety surrounding the German biotech. The shares are still nursing a 14.23% loss over the past month, and at €78.30 on Thursday they stood nearly 10% below the 200-day moving average. The market is not waiting patiently for the company’s transformation from pandemic winner to oncology contender; it wants proof, and the next big test arrives on 29 May in Chicago.

That date marks the presentation of phase 2 data for pumitamig, BioNTech’s bispecific antibody targeting PD-L1 and VEGF-A, at the American Society of Clinical Oncology annual meeting. The drug is being evaluated in the ROSETTA-Lung-02 study against pembrolizumab — Merck’s Keytruda — each combined with chemotherapy, in first-line non-small-cell lung cancer. It is a deliberately high bar: Keytruda is the entrenched standard of care in this setting, so a convincing readout would carry real weight, while a middling or negative result would reinforce doubts about whether BioNTech’s pipeline can deliver value quickly enough.

The competitive field is already taking shape. Pfizer and 3SBio are expected to unveil data for a similar bispecific PD-L1/VEGF-A candidate at the same conference, creating real-time comparisons that will sharpen the judgment on pumitamig’s safety, efficacy and combinability with existing therapies. Beyond lung cancer, BioNTech is running trials with pumitamig in liver, pancreatic, renal cell and glioblastoma tumours — but it is the ASCO snapshot that will set the tone for the near term.

Financially, the company can afford to absorb setbacks. At the end of the first quarter it held €16.8bn ($19.6bn) in cash and cash equivalents, with a debt-to-equity ratio of 0.02 and a market capitalisation of roughly $22.99bn. A $1bn share buyback authorised through May 2027 is also under way. That balance sheet gives management room to fund the oncology pivot while shrinking the equity base, a support mechanism that has helped the stock avoid a steeper slide during a period when many biotech names have come under pressure.

The operating picture, however, remains thin. First-quarter revenue came in at €118.1m, down from €182.8m a year earlier and well below the €171m analysts had pencilled in. The decline in pandemic-related sales is the central drag, and management has pegged full-year revenue at $2.3bn to $2.6bn — a range that underscores how far the topline has shrunk.

That disconnect between financial strength and clinical uncertainty is reflected in the wide spread of analyst targets. Bernstein initiated coverage on 21 May with a Market Perform rating and a $96 target, arguing that its risk-adjusted peak-sales estimate for pumitamig sits roughly 43% below the consensus. Bank of America is more confident with a Buy and $125 target, while H.C. Wainwright sees $130. Canaccord went further at $158, and Leerink is the most cautious at $94. Insider sales of $5.5m over the past three months add to the cautious tone, and the stock’s GF Score of 66 out of 100 offers no strong technical signal.

BioNTech plans to deliver seven late-stage oncology data points this year and aims to have 15 phase 3 studies running by year-end. The pumitamig presentation at ASCO is the first major check-point on that agenda. If the data are robust, the higher price targets will gain traction; if they fall short, Bernstein’s more conservative view will be vindicated. The cash pile can absorb disappointment, but it cannot manufacture conviction. For now, the stock is trading on hope — and on 29 May, hope meets evidence.